other material
confidence high
sentiment neutral
materiality 0.60
Lixte Biotechnology enters $1.7M at-the-market sales agreement with WallachBeth Capital
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
- Entered ATM sales agreement to sell up to $1.7M of common stock.
- Agent commission 3.5% of gross sales; up to $50K expense reimbursement.
- Net proceeds for working capital and development of lead compound LB-100.
- Sales at market prices on Nasdaq or other methods per Rule 415.
- Company not obligated to sell any shares under the agreement.